Longevity Claims in the Beauty Industry Face Growing Scientific Scrutiny
Brands are shifting from anti-aging to biological intervention, raising significant regulatory and evidentiary challenges.
1The Shift to Longevity
The beauty industry is moving beyond traditional anti-aging marketing toward longevity, a structural shift positioning skincare as applied biology. Major players like L’Oréal and Estée Lauder are rebranding aging as a measurable, influenceable biological process. This transition changes how products are researched, priced, and marketed to consumers globally.
2L’Oréal’s Data-Driven Strategy
L’Oréal utilizes its proprietary Longevity AI Cloud to analyze over 260 biomarkers based on twelve hallmarks of aging. The company applies this research to products like Lancôme Absolue, combining DNA-derived ingredients such as PDRN with mitochondrial repair claims. This strategy emphasizes broad, data-backed insights to predict ingredient effects on skin.
3Estée Lauder’s Luxury Focus
Estée Lauder adopts a narrower, luxury-led approach through its Skin Longevity Institute. Focusing on sirtuin biology and energy-boosting delivery systems, the brand repositioned its Re-Nutriv line around SIRTIVITY-LP technology. This platform is supported by over 40 patents and peer-reviewed clinical papers examining facial age assessment models and skincare regimens.
4Borrowing Medical Terminology
Skincare brands are increasingly adopting geroscience terms like NAD+ boosters and sirtuin activators to elevate cosmetic outcomes. However, medical longevity focuses on extending healthspan and preventing chronic disease over decades. Critics argue that applying this vocabulary to topical products used for mere weeks creates a significant credibility gap for consumers.
5AI and Surface Limitations
Many beauty platforms use AI-driven selfie analysis to provide personalized recommendations, yet these tools only measure surface features like wrinkles. They fail to assess internal drivers of aging, such as hormonal shifts or metabolic health. While advanced diagnostics like tape-strip testing emerge, their clinical significance remains subject to independent validation.
6The Regulatory Risk Profile
Under FDA regulations, products claiming to alter the body’s structure or function may be classified as drugs rather than cosmetics. Legal experts warn that referencing cellular repair or biological reversal exposes brands to enforcement actions. Companies must communicate carefully to avoid potential class-action lawsuits and scrutiny from the Federal Trade Commission.
7Historical Precedents of Scrutiny
Regulatory oversight is not new; in 2014, the FTC challenged L’Oréal regarding unsubstantiated gene-related anti-aging claims, leading to a settlement. More recently, the National Advertising Division referred HigherDOSE to authorities after the company declined to participate in inquiries regarding its red light mask claims, highlighting increased accountability for beauty device performance.
8The Longevity Washing Challenge
Industry observers warn of 'longevity washing,' where scientific terminology is used to elevate formulas without corresponding advances in evidence. While the underlying science of sirtuins and senescent cells is legitimate, many active molecules struggle to penetrate the skin barrier effectively, leaving a disconnect between marketing narratives and actual biological impact.
9Future of Market Trust
The longevity claim is beauty’s most powerful yet fragile asset. As scientific authority underpins value propositions, consumers will increasingly demand measurable biological benefits. Brands that successfully integrate rigorous diagnostics, longitudinal data, and honest clinical evidence will likely lead the market, while those relying solely on narrative will face mounting pressure.
Original article: Fortune — Longevity Claims in the Beauty Industry Face Growing Scientific Scrutiny